AMDL Reports Fiscal 2004 Financial Results
March 30 2005 - 11:00PM
PR Newswire (US)
AMDL Reports Fiscal 2004 Financial Results TUSTIN, Calif., March 30
/PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and
marketer of tests for the early detection of cancer and other
serious diseases, today reported its fiscal 2004 financial results.
AMDL's revenues from its DR-70(R) test kit increased to $62,717
compared to $43,828 for the year ended December 31, 2003, an
increase of 43.1%. OEM revenues decreased to $123,465 compared to
$316,279 for the prior year period, a decrease of 61.0%. Total
product revenues for the year ended December 31, 2004 totaled
$186,182, a 48.3% decrease compared to product revenues of $360,107
for the year ended December 31, 2003. Net loss for fiscal 2004 was
$2.6 million or ($0.12) per share compared to a net loss of $2.9
million, or ($0.23) per share, for the year ended December 31,
2003. "The Company's primary objective remains receiving U.S. Food
and Drug Administration clearance to market its DR-70(R) test in
the U.S. FDA approval would simultaneously increase market
awareness and acceptance in international markets," Gary L. Dreher,
CEO of AMDL, said. AMDL recently announced that its consultant,
Diagnostic Oncology Clinical Research Organization (DOCRO), had
submitted to the U.S. Food and Drug Administration, on behalf of
AMDL, additional data in connection with the new application for
510(k) clearance to market AMDL's DR-70(R) test in conjunction with
CEA (carcinoembryonic antigen) as an aid in monitoring patients
previously diagnosed with progressing colorectal cancer.
Specifically, DOCRO submitted data showing that by using DR-70(R)
in conjunction with the CEA test, which is the standard test for
this disease, there is a significant positive gain in sensitivity
of 24% for monitoring the progression of the clinical disease
status in previously diagnosed colorectal cancer patients as
compared to using the CEA test by itself. The CEA test has
sensitivity that varies from 40 to 70 percent, according to
published literature. AMDL is awaiting a response from the FDA.
About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin,
California, is a theranostics company, involved in the detection
and treatment of the same disease, cancer. AMDL is the inventor,
developer and worldwide marketer through exclusive distribution
agreements of the DR-70(R) non-invasive cancer blood test, which
has demonstrated its ability to detect the presence in humans of up
to 13 cancers 84 percent of the time overall. In a study published
in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R)
was shown to detect at least 13 different types of cancer (lung,
breast, stomach, liver, colon, rectal, ovarian, esophageal,
cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic)
although the sample size for 9 of the cancers was not statistically
significant. Clinical trials of DR-70(R) have been conducted in
Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many
kinds of cancer using a single tube of blood, eliminating the need
for costly, multiple tests. AMDL also owns a combination immunogene
therapy technology that is a possible treatment for those already
diagnosed with cancer and could eventually be used as a vaccine to
protect patients known to be at risk because of a family history
for certain types of cancer. The combination therapy both builds
the body's immune system and destroys cancer cells. More
information about AMDL and its additional products can be obtained
at http://www.amdl.com/. Forward-Looking Statements Statements in
this press release may constitute forward-looking statements and
are subject to numerous risks and uncertainties, including the
failure to complete successfully the development of new or enhanced
products, the Company's future capital needs, the lack of market
demand for any new or enhanced products the Company may develop,
any actions by the Company's partners that may be adverse to the
Company, the success of competitive products, other economic
factors affecting the Company and its markets, and other risks
detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. DATASOURCE: AMDL, Inc. CONTACT: Walter Sperr or Pamela
Wadler, +1-212-966-0024, both for AMDL, Inc. Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Aug 2023 to Aug 2024